Get the Stockscreener App
17.63
6.63%
-1.21
Eton Pharmaceuticals Inc stock is traded at $17.63, with a volume of 367.75K.
It is down -6.63% in the last 24 hours and up +1.44% over the past month.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
See More
Previous Close:
$18.84
Open:
$19.02
24h Volume:
367.75K
Relative Volume:
1.33
Market Cap:
$471.36M
Revenue:
$31.38M
Net Income/Loss:
$-6.69M
P/E Ratio:
-67.81
EPS:
-0.26
Net Cash Flow:
$-1.84M
1W Performance:
-12.23%
1M Performance:
+1.44%
6M Performance:
+48.82%
1Y Performance:
+384.57%
1-Day Range:
$17.26
$19.02
1-Week Range:
$17.26
$21.10
52-Week Range:
$3.18
$21.48
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Name
Eton Pharmaceuticals Inc
Sector
Phone
(847) 787-7361
Address
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
17.57 | 537.42M | 31.38M | -6.69M | -1.84M | -0.26 |
|
HLN
Haleon Plc Adr
|
11.06 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
170.83 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.8576 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Reiterated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | B. Riley Securities | Buy |
| Jan-06-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-04-24 | Resumed | H.C. Wainwright | Buy |
| May-06-24 | Initiated | Craig Hallum | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Jan-04-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-20-19 | Initiated | B. Riley FBR | Buy |
| Jun-10-19 | Initiated | H.C. Wainwright | Buy |
View All
Eton Pharmaceuticals Inc Stock (ETON) Latest News
Eton Pharmaceuticals (ETON) Upgraded to Buy: Here's Why - MSN
Millennium Management LLC Acquires New Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Eton Pharmaceuticals (ETON) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Equities Analysts Offer Predictions for ETON Q3 Earnings - Defense World
Eton Pharmaceuticals, Inc. (ETON) Launches Game-Changer for Adrenal Insufficiency - MSN
Eton Pharmaceuticals (ETON) Target Price Raised to $35 by HC Wai - GuruFocus
Eton Pharmaceuticals Inc (ETON) Shares Down 4.98% on May 29 - GuruFocus
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue - Benzinga
Sector Update: Health Care - marketscreener.com
Eton Pharmaceuticals stock rises on FDA approval of KHINDIVI By Investing.com - Investing.com South Africa
Northern Trust Corp Purchases 22,827 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Eton Pharmaceuticals stock rises on FDA approval of KHINDIVI - Investing.com Australia
Eton Pharma stock gains on FDA nod for Khindivi (ETON:NASDAQ) - Seeking Alpha
Eton Pharmaceuticals (ETON) Price Target Raised After FDA Approval | ETON Stock News - GuruFocus
Eton Pharmaceuticals Gains FDA Approval for KHINDIVI - TipRanks
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution - GlobeNewswire
Trading (ETON) With Integrated Risk Controls - news.stocktradersdaily.com
Jane Street Group LLC Has $857,000 Stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
individual investors who own 43% along with institutions invested in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) saw increase in their holdings value last week - Yahoo Finance
Eton Pharmaceuticals Set To Dominate Orphan Drug Niche (NASDAQ:ETON) - Seeking Alpha
Eton Pharmaceuticals Inc (ETON) Shares Up 3.33% on May 19 - GuruFocus
Balyasny Asset Management L.P. Invests $158,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Q3 EPS Estimates for Eton Pharmaceuticals Cut by B. Riley - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Earns “Buy” Rating from B. Riley - Defense World
Eton Pharmaceuticals Inc (ETON) Shares Down 3.4% on May 16 - GuruFocus
(ETON) Trading Report - news.stocktradersdaily.com
Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $28.00 - Defense World
HC Wainwright Has Negative Outlook of ETON Q2 Earnings - Defense World
Eton Pharmaceuticals (ETON) Price Target Raised by B. Riley Secu - GuruFocus
Eton Pharmaceuticals (ETON) Price Target Raised by B. Riley Securities | ETON Stock News - GuruFocus
Eton Pharmaceuticals (ETON) Price Target Boosted Following Strong Q1 Results | ETON Stock News - GuruFocus
Results: Eton Pharmaceuticals, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts - simplywall.st
B. Riley Raises Price Target on Eton Pharmaceuticals to $26 From $24, Keeps Buy Rating - marketscreener.com
Eton Pharmaceuticals (NASDAQ:ETON) Trading Up 12% After Analyst Upgrade - Defense World
Eton outlines path to $100M near-term revenue with ET-400 launch and Increlex growth - MSN
Eton Pharmaceuticals’ Earnings Call: Growth and Prospects - TipRanks
Eton Pharmaceuticals (ETON) Price Target Raised by Craig-Hallum | ETON Stock News - GuruFocus
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2025 Earnings Call Transcript - Insider Monkey
Eton Pharmaceuticals (NASDAQ:ETON) Sets New 12-Month High Following Analyst Upgrade - Defense World
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences - GlobeNewswire
Eton Pharmaceuticals CEO to Lead Fireside Chat at Major Investor Conferences: How to Schedule 1-on-1 Meetings - Stock Titan
Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates - MSN
A Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 Analysts - Benzinga
Eton Pharmaceuticals Secures Major Revenue Growth In Q1, Launches ET-400 In Sight - Nasdaq
Eton Pharmaceuticals (ETON) Surpasses Q1 Revenue Expectations wi - GuruFocus
Eton Pharmaceuticals: Buy Rating Backed by Successful Relaunches and Promising Growth Prospects - TipRanks
Raymond James Financial Inc. Takes $147,000 Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Eton Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks
Eton Pharmaceuticals (ETON) Projects Strong Growth with New Acqu - GuruFocus
Eton Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Eton Pharmaceuticals Q1 2025 beats revenue estimates - Investing.com Nigeria
Eton Pharmaceuticals Inc Stock (ETON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eton Pharmaceuticals Inc Stock (ETON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Oct 23 '24 |
Buy |
7.98 |
10,000 |
79,814 |
2,770,000 |
| Opaleye Management Inc. | 10% Owner |
Oct 08 '24 |
Buy |
7.03 |
33,970 |
238,782 |
2,760,000 |
| Opaleye Management Inc. | 10% Owner |
Oct 04 '24 |
Buy |
6.77 |
16,852 |
114,105 |
2,720,000 |
| Opaleye Management Inc. | 10% Owner |
Oct 07 '24 |
Buy |
7.22 |
11,248 |
81,250 |
2,730,000 |
| Opaleye Management Inc. | 10% Owner |
Sep 10 '24 |
Buy |
4.65 |
57,500 |
267,375 |
2,660,000 |
| Opaleye Management Inc. | 10% Owner |
Sep 11 '24 |
Buy |
4.75 |
50,000 |
237,500 |
2,705,000 |
3.28%
2.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):